How many Lazertinib clinical trials are there?

40 Lazertinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants. 11 are marked completed.

Are Lazertinib clinical trials recruiting in 2026?

Yes — 7 Lazertinib trials are actively recruiting in 2026, with 147 U.S. sites across 32 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Lazertinib being studied for?

Lazertinib is being studied for Carcinoma, Non-Small-Cell Lung, Healthy, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC and 20 more. The trials are grouped by indication on this page.

What phase is Lazertinib in?

Lazertinib clinical trials span 4 Phase 3, 22 Phase 2, 9 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Lazertinib clinical trials?

The lead sponsor across the most Lazertinib trials is Janssen Research & Development, LLC, with 13 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Lazertinib Clinical Trials (2026): 40 Studies for Carcinoma, Non-Small-Cell Lung & Healthy

Creator: Hipa.ai Research
Published: 2026-05-07T20:06:22.059Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

40 Lazertinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 21 indications (including Carcinoma, Non-Small-Cell Lung & Healthy) and 8,913 total planned enrollment. 4 Phase 3 Lazertinib trials and 22 Phase 2 are listed. 8 Lazertinib clinical trials are actively recruiting at 147 U.S. sites across 32 states. Most recent activity: NCT06120140 (Jan 2032).

Where to Participate: All Lazertinib Trial Sites in the U.S. (147 sites across 32 states)

Every actively recruiting Lazertinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Southern Cancer Center, PC	Daphne36526	NCT06667076	Map
AL	Clearview Cancer Institute	Huntsville35805	NCT06667076	Map
AZ	City of Hope Phoenix	Goodyear85338	NCT06667076	Map
CA	The Oncology Institute of Hope and Innovation	Cerritos90703	NCT06667076	Map
CA	City of Hope Corona	Corona92882	NCT06667076	Map
CA	City of Hope	Duarte91010	NCT06667076	Map
CA	Providence Medical Foundation	Fullerton92835	NCT06667076	Map
CA	Glendale Adventist Medical Center	Glendale91206	NCT06667076	Map
CA	Los Angeles Cancer Network	Glendale91204	NCT06667076	Map
CA	Marin Cancer Center	Greenbrae94904	NCT06667076	Map
CA	City of Hope Seacliff	Huntington Beach92648	NCT06667076	Map
CA	City of Hope Orange County Lennar Foundation Cancer Center	Irvine92618	NCT06667076	Map
CA	University of California at San Diego	La Jolla92093	NCT05498428	Map
CA	University of California San Diego Health	La Jolla92093	NCT06667076	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT06667076	Map
CA	City of Hope Long Beach Elm	Long Beach90813	NCT06667076	Map
CA	Cancer and Blood Specialty Clinic	Los Alamitos90720	NCT06667076	Map
CA	Cedars Sinai Medical Center	Los Angeles90048	NCT06667076	Map
CA	USC Norris Comprehensive Cancer Center	Los Angeles90033	NCT06667076	Map
CA	Valkyrie Clinical Trials	Los Angeles90067	NCT06667076	Map
CA	Valkyrie Clinical Trials Murrieta	Murrieta92562	NCT06667076	Map
CA	Kaiser Permanente Oakland Medical Center	Oakland94611	NCT06667076	Map
CA	St. Joseph Hospital Center for Cancer Prevention and Treatment	Orange92868	NCT06667076	Map
CA	University of California Irvine	Orange92868	NCT05498428	Map
CA	University of California Irvine	Orange92868	NCT06667076	Map
CA	Sutter Health Palo Alto Medical Foundation	Palo Alto94301	NCT06667076	Map
CA	Kaiser Permanente Roseville Medical Center	Roseville95661	NCT06667076	Map
CA	Sutter Institute for Medical Research	Sacramento95816	NCT06667076	Map
CA	UC Davis Comprehensive Cancer Center	Sacramento95630	NCT06667076	Map
CA	California Pacific Medical Center	San Francisco94115	NCT06667076	Map
CA	Kaiser Permanente San Francisco Medical Center	San Francisco94115	NCT06667076	Map
CA	UCSF Zuckerberg San Francisco General Hospital	San Francisco94143	NCT06667076	Map
CA	Sansum Clinic	Santa Barbara93105	NCT06667076	Map
CA	Kaiser Permanente Santa Clara Medical Center	Santa Clara95051	NCT06667076	Map
CA	Providence Medical Foundation 1	Santa Rosa95403	NCT06667076	Map
CA	City of Hope South Pasadena	South Pasadena91030	NCT06667076	Map
CA	Stanford Cancer Institute	Stanford94305	NCT05498428	Map
CA	City of Hope Upland	Upland91786	NCT06667076	Map
CA	Kaiser Permanente Northern California	Vallejo94589	NCT06667076	Map
CA	John Muir Health Clinical Research Center	Walnut Creek94598	NCT06667076	Map
CA	Kaiser Permanente Walnut Creek Medical Center	Walnut Creek94596	NCT06667076	Map
CO	Rocky Mountain Cancer Centers	Lone Tree80124	NCT06667076	Map
CT	Yale New Haven Hospital Yale Cancer Center	New Haven06520	NCT06667076	Map
DE	ChristianaCare Helen F Graham Cancer Center and Research Institute	Newark19713	NCT06667076	Map
DC	Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital	Washington D.C.20016	NCT05498428	Map
DC	MedStar Georgetown University Hospital	Washington D.C.20007	NCT06667076	Map
DC	Washington DC VA Medical Center	Washington D.C.20422	NCT06667076	Map
FL	Baptist Lynn Cancer Institute	Boca Raton33486	NCT06667076	Map
FL	The Oncology Institute of Hope and Innovation 1	Fort Lauderdale33316	NCT06667076	Map
FL	Florida Cancer Specialists	Fort Myers33916	NCT06667076	Map
FL	Univ of Florida	Gainesville32610	NCT06667076	Map
FL	Memorial Regional Hospital	Hollywood33021 5421	NCT06667076	Map
FL	Baptist MD Anderson Cancer Center	Jacksonville32207	NCT06667076	Map
FL	Mayo Clinic	Jacksonville32224	NCT06667076	Map
FL	Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology	Lake City32024-3456	NCT05541822	Map
FL	Baptist Health Miami Cancer Institute	Miami33176	NCT06667076	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT06667076	Map
FL	Mount Sinai Medical Center	Miami Beach33140	NCT05498428	Map
FL	Mid Florida Center	Orange City32763-8316	NCT05541822	Map
FL	AdventHealth	Orlando32804	NCT05498428	Map
FL	AdventHealth Orlando	Orlando32803	NCT06667076	Map
FL	Orlando Health Cancer Institute	Orlando32806	NCT06667076	Map
FL	Memorial Cancer Institute	Pembroke Pines33026	NCT06667076	Map
FL	Florida Cancer Specialists & Research Institute 1	St. Petersburg33701	NCT06667076	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06667076	Map
FL	Florida Cancer Specialists & Research Institute	West Palm Beach33401	NCT06667076	Map
GA	University Cancer And Blood Center LLC	Athens30607	NCT06667076	Map
GA	Grady Health System Correll Pavilion	Atlanta30303	NCT06667076	Map
GA	Piedmont Cancer Institute	Atlanta30318	NCT06667076	Map
GA	Piedmont Healthcare	Atlanta30309	NCT06667076	Map
GA	Winship Cancer Institute Emory University	Atlanta30322	NCT06667076	Map
GA	City of Hope Cancer Center	Newnan30265	NCT06667076	Map
IL	Rush University Medical Center Rush University Cancer Center Chicago	Chicago60607	NCT06667076	Map
IL	University of Illinois at Chicago	Chicago60612	NCT06667076	Map
IL	Cancer Care Specialists of Central Illinois	Decatur62526	NCT06667076	Map
IL	Illinois Cancer Specialists	Niles60714	NCT06667076	Map
IL	Illinois CancerCare	Peoria61615	NCT06667076	Map
IL	City of Hope Chicago	Zion60099	NCT06667076	Map
IN	Fort Wayne Medical Oncology and Hematology	Fort Wayne46804	NCT06667076	Map
IN	Investigative Clinical Research of Indiana, LLC	Noblesville46062	NCT06667076	Map
IA	Accellacare of McFarland	Ames50010	NCT06667076	Map
KS	University of Kansas Cancer Center	Fairway66205	NCT06667076	Map
KS	University of Kansas Cancer Center	Westwood66205	NCT05498428	Map
MD	Sidney Kimmel Cancer Center - Bayview Campus	Baltimore21224	NCT05498428	Map
MD	University of Maryland	Baltimore21201	NCT06667076	Map
MD	Maryland Oncology Hematology P A	Silver Spring20904	NCT06667076	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06667076	Map
MA	Boston Medical Center	Boston02118	NCT05498428	Map
MA	Boston University Medical Center	Boston02118	NCT06667076	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06667076	Map
MI	University of Michigan Health System	Ann Arbor48105	NCT06667076	Map
MI	Trinity Health St Joseph Mercy Ann Arbor	Ypsilanti48197	NCT06667076	Map
MN	University Of Minnesota	Minneapolis55455	NCT06667076	Map
MN	Mayo Clinic Rochester	Rochester55905	NCT06667076	Map
MO	Truman Medical Ctr West	Kansas City64108	NCT06667076	Map
MO	Oncology Hematology Associates	Springfield65807	NCT06667076	Map
MO	Washington University School Of Medicine	St Louis63110	NCT05498428	Map
MO	Washington University School Of Medicine	St Louis63110	NCT06667076	Map
NH	Dartmouth Hitchcock Medical Center	Lebanon03756	NCT06667076	Map
NJ	Hackensack University Medical Center	Hackensack07601	NCT05498428	Map
NJ	Morristown Medical Center	Morristown07960	NCT06667076	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT05498428	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT06667076	Map
NJ	Overlook Medical Center	Summit07901	NCT06667076	Map
NM	University of New Mexico	Albuquerque87102	NCT06667076	Map
NY	Hematology-Oncology Associates of CNY	East Syracuse13057	NCT06667076	Map
NY	Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island	Mineola11501	NCT06667076	Map
NY	Herbert Irving Comprehensive Cancer Center Columbia University Medical Center	New York10032	NCT06667076	Map
NY	NYU Langone Health Laura and Isaac Perlmutter Cancer Center	New York10016	NCT06667076	Map
NY	Ellis Hospital	Schenectady12308	NCT06667076	Map
NY	New York Cancer and Blood Specialists	Shirley11967	NCT06667076	Map
NY	Montefiore Medical Center	The Bronx10461	NCT06667076	Map
NC	Atrium Health	Charlotte28204	NCT06667076	Map
NC	Regional Medical Oncology Center	Wilson27893	NCT06667076	Map
NC	Atrium Health Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem27157	NCT06667076	Map
OH	Cincinnati Veterans Affairs Medical Center	Cincinnati45220	NCT06667076	Map
OR	Oncology Associates of Oregon PC Willamette Valley Cancer Institute	Eugene97401	NCT06667076	Map
OR	Oregon Health And Science University	Portland97239	NCT06667076	Map
PA	Jefferson Health Northeast	Philadelphia19114	NCT06667076	Map
PA	Philadelphia VA Medical Center	Philadelphia19104	NCT06667076	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT06667076	Map
PA	McGlinn Cancer Institute Reading Hospital	West Reading19611	NCT06667076	Map
SC	Medical University of South Carolina	Charleston29425	NCT06667076	Map
TN	Tennessee Oncology - Chattanooga	Chattanooga37404	NCT06667076	Map
TN	Tennessee Cancer Specialists	Knoxville37909	NCT06667076	Map
TN	University of Tennessee	Knoxville37920	NCT06667076	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06667076	Map
TN	Tennessee Oncology	Nashville37203	NCT06667076	Map
TX	Texas Oncology South	Austin78745	NCT06667076	Map
TX	Parkland Health and Hospital System	Dallas75235	NCT06667076	Map
TX	Texas Oncology DFW	Dallas75246	NCT06667076	Map
TX	UT Southwestern Medical Center	Dallas75390	NCT06667076	Map
TX	JPS Health Network	Fort Worth76104	NCT06667076	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06667076	Map
TX	Oncology Consultants Texas	Houston77030	NCT06667076	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030-4000	NCT05541822	Map
TX	Community Clinical Trials	Kingwood77339	NCT06667076	Map
TX	Texas Oncology San Antonio Northeast	San Antonio78217	NCT06667076	Map
TX	Texas Oncology - Northeast	Tyler75702	NCT06667076	Map
TX	The University of Texas Health Science Center at Tyler	Tyler75701	NCT06667076	Map
TX	Texas Oncology-Gulf Coast	Webster77598	NCT06667076	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT06667076	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT05498428	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT06667076	Map
WA	Vista Oncology	Olympia98506	NCT06667076	Map
WA	Swedish Cancer Institute	Seattle98104	NCT05498428	Map
WA	Summit Cancer Centers	Spokane99208	NCT06667076	Map

Lazertinib clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	not yet recruiting	unknown	approved for marketing	Total
P1		2	7				9
P1/P2			1				1
P2	7	6	1	1	7		22
P3		3	1				4
N/A			1		2	1	4

Recruiting Lazertinib clinical trials (8)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07507188	INSTARCollaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)	P2	Non Small Cell Lung Cancer	80	Apr 2026
NCT06667076	COPERNICUSA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	P2	Carcinoma, Non-Small-Cell Lung	480	Dec 2024
NCT06106802	Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment	P2	Non-Small Cell Lung Cancer Metastatic	47	Jun 2024
NCT05541822	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation	P2	Advanced Solid Tumors	178	Jan 2023
NCT05498428	PALOMA-2A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer	P2	Carcinoma, Non-small-Cell Lung	520	Nov 2022
NCT06268210	NeoLazerNeoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer	P2	Non-small Cell Lung Cancer	160	Feb 2022
NCT05469022	Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy	P2	Non Small Cell Lung Cancer	40	May 2022
NCT06156527	A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker	P2	Lazertinib	120	Sep 2023

Lazertinib clinical trials by indication

Carcinoma, Non-Small-Cell Lung (7)

NCT	Acronym	Phase	Status	Title
NCT06120140	COCOON	P2	active not recruiting	Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06667076	COPERNICUS	P2	recruiting	A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT04077463	Chrysalis-2	P1	active not recruiting	A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04988295	MARIPOSA-2	P3	active not recruiting	A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04487080	MARIPOSA	P3	active not recruiting	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT05663866	—	P2	active not recruiting	Premedication to Reduce Amivantamab Associated Infusion Related Reactions
NCT04075396	EGFR	P1/P2	completed	A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT07507188	INSTAR	P2	not yet recruiting	Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)
NCT05469022	—	P2	recruiting	Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
NCT05601973	AMAZE-lung	P2	active not recruiting	Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
NCT06020989	CHAMELEON	P2	unknown	Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
NCT05167851	—	P2	unknown	The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Healthy (5)

NCT	Acronym	Phase	Status	Title
NCT05896683	JNJ-73841937	P1	completed	A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
NCT05742594	JNJ-73841937	P1	completed	A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
NCT05076877	JNJ-73841937	P1	completed	A Study of Lazertinib (JNJ-73841937) in Healthy Participants
NCT04410081	—	P1	completed	A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants
NCT04410094	—	P1	completed	A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

Non-small Cell Lung Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT06268210	NeoLazer	P2	recruiting	Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
NCT05786430	LUCAS	P2	active not recruiting	Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib
NCT05716672	—	N/A	unknown	Impact of Lazertinib Dose Modification on Effectiveness and Safety
NCT05477615	—	P2	unknown	Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
NCT05862194	—	N/A	completed	Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

NSCLC (2)

NCT	Acronym	Phase	Status	Title
NCT05463224	—	P2	active not recruiting	Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
NCT05277701	LU21-16	P2	unknown	Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations

Non-Small Cell Lung Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT06106802	—	P2	recruiting	Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Lazertinib (1)

NCT	Acronym	Phase	Status	Title
NCT06156527	—	P2	recruiting	A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Metastatic Non-small Cell Lung Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT05299125	AMIGO-1	P2	active not recruiting	Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

Lung Cancer Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT05701384	—	P2	unknown	Lazertinib 160mg in EGFR T790M NSCLC

Advanced Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT05541822	—	P2	recruiting	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Carcinoma, Non-small-Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT05498428	PALOMA-2	P2	recruiting	A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Advanced or Metastatic Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05388669	PALOMA-3	P3	active not recruiting	A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05377788	—	N/A	unknown	Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT05338619	PLATINUM	P2	unknown	A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Healthy Adult Volunteers (1)

NCT	Acronym	Phase	Status	Title
NCT05162274	—	P1	completed	Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

Hepatic Impairment (1)

NCT	Acronym	Phase	Status	Title
NCT05112952	JNJ-73841937	P1	completed	A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)

Metastatic Non Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04965090	NSCLC	P2	completed	A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Lung Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT05326425	—	P2	unknown	Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04248829	LASER301	P3	completed	Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small-Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02609776	CHRYSALIS	P1	active not recruiting	Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04829422	—	N/A	approved for marketing	Early Access Program of Lazertinib in Republic of Korea

Lazertinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
MARIPOSA-2	NCT04988295	P3	active not recruiting	Carcinoma, Non-Small-Cell Lung	776	—
MARIPOSA	NCT04487080	P3	active not recruiting	Carcinoma, Non-Small-Cell Lung	1,074	PMID 40923797
PALOMA-3	NCT05388669	P3	active not recruiting	Advanced or Metastatic Non-small Cell Lung Cancer	418	PMID 38857463
LASER301	NCT04248829	P3	completed	Non-Small Cell Lung Cancer	393	PMID 37865896
COCOON	NCT06120140	P2	active not recruiting	Carcinoma, Non-Small-Cell Lung	305	—
INSTAR	NCT07507188	P2	not yet recruiting	Non Small Cell Lung Cancer	80	—
COPERNICUS	NCT06667076	P2	recruiting	Carcinoma, Non-Small-Cell Lung	480	—
PALOMA-2	NCT05498428	P2	recruiting	Carcinoma, Non-small-Cell Lung	520	—
NeoLazer	NCT06268210	P2	recruiting	Non-small Cell Lung Cancer	160	—
AMIGO-1	NCT05299125	P2	active not recruiting	Metastatic Non-small Cell Lung Cancers	54	—
AMAZE-lung	NCT05601973	P2	active not recruiting	Non Small Cell Lung Cancer	60	—
LUCAS	NCT05786430	P2	active not recruiting	Non-small Cell Lung Cancer	87	—
PLATINUM	NCT05338619	P2	unknown	Non-small Cell Lung Cancer Stage III	77	PMID 36268845
CHAMELEON	NCT06020989	P2	unknown	Non Small Cell Lung Cancer	129	—
NSCLC	NCT04965090	P2	completed	Metastatic Non Small Cell Lung Cancer	43	PMID 41139066
LU21-16	NCT05277701	P2	unknown	NSCLC	36	—

All Lazertinib trials (40)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06120140	COCOON	Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib	P2	active not recruiting	305	Janssen Research & Development, LLC	Feb 2024
NCT07507188	INSTAR	Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)	P2	not yet recruiting	80	Yonsei University	Apr 2026
NCT06667076	COPERNICUS	A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	P2	recruiting	480	Janssen Research & Development, LLC	Dec 2024
NCT06106802		Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment	P2	recruiting	47	Samsung Medical Center	Jun 2024
NCT05541822		To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation	P2	recruiting	178	Abion Inc	Jan 2023
NCT05498428	PALOMA-2	A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer	P2	recruiting	520	Janssen Research & Development, LLC	Nov 2022
NCT06268210	NeoLazer	Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer	P2	recruiting	160	Yonsei University	Feb 2022
NCT04077463	Chrysalis-2	A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer	P1	active not recruiting	701	Janssen Research & Development, LLC	Sep 2019
NCT05463224		Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients	P2	active not recruiting	150	Se-Hoon Lee	Jan 2023
NCT04988295	MARIPOSA-2	A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure	P3	active not recruiting	776	Janssen Research & Development, LLC	Nov 2021
NCT04487080	MARIPOSA	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	P3	active not recruiting	1,074	Janssen Research & Development, LLC	Sep 2020
NCT05299125	AMIGO-1	Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations	P2	active not recruiting	54	Latin American Cooperative Oncology Group	May 2023
NCT05388669	PALOMA-3	A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer	P3	active not recruiting	418	Janssen Research & Development, LLC	Aug 2022
NCT05469022		Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy	P2	recruiting	40	Konkuk University Medical Center	May 2022
NCT05663866		Premedication to Reduce Amivantamab Associated Infusion Related Reactions	P2	active not recruiting	68	Janssen Research & Development, LLC	May 2023
NCT06156527		A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker	P2	recruiting	120	National Cancer Center, Korea	Sep 2023
NCT02609776	CHRYSALIS	Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer	P1	active not recruiting	751	Janssen Research & Development, LLC	May 2016
NCT05601973	AMAZE-lung	Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI	P2	active not recruiting	60	ETOP IBCSG Partners Foundation	Mar 2023
NCT05786430	LUCAS	Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib	P2	active not recruiting	87	Yonsei University	Apr 2023
NCT04248829	LASER301	Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)	P3	completed	393	Yuhan Corporation	Feb 2020
NCT05338619	PLATINUM	A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy	P2	unknown	77	Sung Yong Lee	Jun 2022
NCT06020989	CHAMELEON	Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy	P2	unknown	129	Yonsei University	Sep 2023
NCT05716672		Impact of Lazertinib Dose Modification on Effectiveness and Safety	—	unknown	200	Pusan National University Hospital	Feb 2023
NCT05167851		The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer	P2	unknown	68	Yonsei University	Dec 2021
NCT04965090	NSCLC	A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)	P2	completed	43	Memorial Sloan Kettering Cancer Center	Sep 2021
NCT05477615		Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases	P2	unknown	28	Jin Hyoung Kang	Aug 2022
NCT05701384		Lazertinib 160mg in EGFR T790M NSCLC	P2	unknown	117	Samsung Medical Center	Feb 2023
NCT05277701	LU21-16	Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations	P2	unknown	36	Yonsei University	Apr 2022
NCT05377788		Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer	—	unknown	900	Samsung Medical Center	Jul 2022
NCT05326425		Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.	P2	unknown	40	Jin Hyoung Kang	Jun 2021
NCT05896683	JNJ-73841937	A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants	P1	completed	72	Janssen Research & Development, LLC	May 2023
NCT05742594	JNJ-73841937	A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants	P1	completed	64	Janssen Research & Development, LLC	Jan 2023
NCT05862194		Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC	—	completed	534	Yuhan Corporation	Jun 2015
NCT04075396	EGFR	A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)	P1/P2	completed	29	Janssen Research & Development, LLC	Oct 2019
NCT05112952	JNJ-73841937	A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)	P1	completed	16	Janssen Research & Development, LLC	Nov 2021
NCT05076877	JNJ-73841937	A Study of Lazertinib (JNJ-73841937) in Healthy Participants	P1	completed	20	Janssen Research & Development, LLC	Sep 2021
NCT05162274		Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.	P1	completed	38	Yuhan Corporation	Nov 2021
NCT04829422		Early Access Program of Lazertinib in Republic of Korea	—	approved for marketing	0	Yuhan Corporation	—
NCT04410081		A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants	P1	completed	8	Janssen Research & Development, LLC	Jul 2020
NCT04410094		A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants	P1	completed	32	Janssen Research & Development, LLC	Sep 2020

Lazertinib clinical trials: frequently asked questions

How many Lazertinib clinical trials are there?: 40 Lazertinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants. 11 are marked completed.
Are Lazertinib clinical trials recruiting in 2026?: Yes — 7 Lazertinib trials are actively recruiting in 2026, with 147 U.S. sites across 32 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Lazertinib being studied for?: Lazertinib is being studied for Carcinoma, Non-Small-Cell Lung, Healthy, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC and 20 more. The trials are grouped by indication on this page.
What phase is Lazertinib in?: Lazertinib clinical trials span 4 Phase 3, 22 Phase 2, 9 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Lazertinib clinical trials?: The lead sponsor across the most Lazertinib trials is Janssen Research & Development, LLC, with 13 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Lazertinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Lazertinib overview Lazertinib evidence & publications